[go: up one dir, main page]

PE20021014A1 - GLUTARAMIDE DERIVATIVES SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO AS NEP INHIBITORS FOR FSAD - Google Patents

GLUTARAMIDE DERIVATIVES SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO AS NEP INHIBITORS FOR FSAD

Info

Publication number
PE20021014A1
PE20021014A1 PE2002000240A PE2002000240A PE20021014A1 PE 20021014 A1 PE20021014 A1 PE 20021014A1 PE 2002000240 A PE2002000240 A PE 2002000240A PE 2002000240 A PE2002000240 A PE 2002000240A PE 20021014 A1 PE20021014 A1 PE 20021014A1
Authority
PE
Peru
Prior art keywords
alkyl
cyclopentilo
fenpropyl
fsad
derivatives substituted
Prior art date
Application number
PE2002000240A
Other languages
Spanish (es)
Inventor
Stephen Challenger
Andrew Simon Cook
Adam Thomas Gillmore
David Cameron Pryde
Alan Stobie
Donald Stuart Middleton
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0107750A external-priority patent/GB0107750D0/en
Priority claimed from GB0113112A external-priority patent/GB0113112D0/en
Priority claimed from GB0120152A external-priority patent/GB0120152D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20021014A1 publication Critical patent/PE20021014A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/82—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE GLUTARAMIDA SUSTITUIDA CON N-FENPROPILCICLOPENTILO DE FORMULA I DONDE R1 ES ALQUILO C1-C6 CON HALO, HIDROXI, ALCOXI C1-C6, NR2R3, NR4SO2R5, ENTRE OTROS; R2 Y R3 SON CARBOCICLICO, HETEROCICLICLO CON ALQUILO C1-C4, ENTRE OTROS; R4 ES H, ALQUILO C1-C4; R5 ES ALQUILO C1-C4, CF3, CARBOCICLICO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS ACIDO (2R)-2-{[1-({[3-(4-METOXIFENIL)PROPIL]AMINO}CARBONIL)CICLOPENTIL]METIL}-PENTANOICO, ACIDO 3-{[1-({[3-(4-METOXIFENIL)PROPIL]AMINO}CARBONIL)CICLOPENTIL]PROPANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LA ENZIMA ENDOPEPTIDASA NEUTRA (NEP) Y SON UTILES PARA EL TRATAMIENTO DE DISFUNCION SEXUAL (FSAD)REFERS TO DERIVATIVES OF GLUTARAMIDE SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO OF FORMULA I WHERE R1 IS C1-C6 ALKYL WITH HALO, HYDROXY, C1-C6 ALCOXY, NR2R3, NR4SO2R5, AMONG OTHERS; R2 AND R3 ARE CARBOCYCLIC, HETERO CYCLE WITH C1-C4 ALKYL, AMONG OTHERS; R4 IS H, C1-C4 ALKYL; R5 IS C1-C4, CF3, CARBOCYCLIC, ALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE (2R) -2 - {[1 - ({[3- (4-METOXYPHENYL) PROPYL] AMINO} CARBONYL) CYCLOPENTIL] METHYL} -PENTANOIC ACID, 3 - {[1 - ({[3- ( 4-METHOXYPHENIL) PROPYL] AMINO} CARBONYL) CYCLOPENTIL] PROPANOIC, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PROCEDURE FOR THE PREPARATION. THE MENTIONED COMPOUNDS ARE INHIBITORS OF NEUTRAL ENZYME ENDOPEPTIDASE (NEP) AND ARE USEFUL FOR THE TREATMENT OF SEXUAL DYSFUNCTION (FSAD)

PE2002000240A 2001-03-28 2002-03-26 GLUTARAMIDE DERIVATIVES SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO AS NEP INHIBITORS FOR FSAD PE20021014A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0107750A GB0107750D0 (en) 2001-03-28 2001-03-28 Novel pharmaceuticals
GB0113112A GB0113112D0 (en) 2001-05-30 2001-05-30 Novel pharmaceuticals
GB0120152A GB0120152D0 (en) 2001-08-17 2001-08-17 Novel pharmaceuticals

Publications (1)

Publication Number Publication Date
PE20021014A1 true PE20021014A1 (en) 2002-11-12

Family

ID=27256128

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000240A PE20021014A1 (en) 2001-03-28 2002-03-26 GLUTARAMIDE DERIVATIVES SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO AS NEP INHIBITORS FOR FSAD

Country Status (33)

Country Link
EP (1) EP1373192A1 (en)
JP (1) JP4018545B2 (en)
KR (1) KR100564466B1 (en)
CN (1) CN1243723C (en)
AP (1) AP1689A (en)
AR (1) AR035795A1 (en)
BG (1) BG108130A (en)
BR (1) BR0208455A (en)
CA (1) CA2437113A1 (en)
CZ (1) CZ20032534A3 (en)
DO (1) DOP2002000364A (en)
EA (1) EA006154B1 (en)
EE (1) EE200300469A (en)
GE (1) GEP20063783B (en)
HR (1) HRP20030751A2 (en)
HU (1) HUP0303624A3 (en)
IL (1) IL157009A0 (en)
IS (1) IS6877A (en)
MA (1) MA26996A1 (en)
MX (1) MXPA03006597A (en)
MY (1) MY134081A (en)
NO (1) NO20034299L (en)
NZ (1) NZ527012A (en)
OA (1) OA12553A (en)
PA (1) PA8542401A1 (en)
PE (1) PE20021014A1 (en)
PL (1) PL365101A1 (en)
RS (1) RS75303A (en)
SK (1) SK11822003A3 (en)
TN (1) TNSN02032A1 (en)
TW (1) TWI254038B (en)
UY (1) UY27227A1 (en)
WO (1) WO2002079143A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20030118633A1 (en) * 2001-11-09 2003-06-26 Ebrahim Versi Combination therapy
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0230025D0 (en) * 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
GB0230036D0 (en) * 2002-12-23 2003-01-29 Pfizer Ltd Novel pharmaceuticals
PA8597401A1 (en) * 2003-03-14 2005-05-24 Pfizer ACID DERIVATIVES 3- (1- [3- (1,3-BENZOTIAZOL-6-IL) PROPILCARBAMOIL] CICLOALQUIL) PROPANOIC AS NEP INHIBITORS
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
PT1750766E (en) 2004-05-11 2013-09-30 Emotional Brain Bv Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006027680A1 (en) * 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
EP1945214A1 (en) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
ES2336719T3 (en) 2006-06-30 2010-04-15 Boehringer Ingelheim International Gmbh FLIBANSERINE FOR THE TREATMENT OF URINARY INCONTINENCE AND RELATED DISEASES.
JP5793828B2 (en) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Formulation of flibanserin and method for producing the same
AR062321A1 (en) 2006-08-25 2008-10-29 Boehringer Ingelheim Int CONTROLLED RELEASE SYSTEM AND METHOD TO MANUFACTURE
CN101573340A (en) * 2006-11-01 2009-11-04 百时美施贵宝公司 Modulators of glucocorticoid receptor AP-1 and/or NF-kB activity and uses thereof
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
PE20091188A1 (en) 2007-09-12 2009-08-31 Boehringer Ingelheim Int COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN
US8993631B2 (en) 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8877815B2 (en) * 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PH12017502158B1 (en) 2015-06-03 2022-04-27 Bristol Meyers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
US10912778B2 (en) 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN107746400A (en) * 2017-12-04 2018-03-02 武汉药明康德新药开发有限公司 The preparation method of the sulfonic acid chloride of benzodihydropyran 6
SMT202200134T1 (en) 2018-03-08 2022-05-12 Incyte Corp Aminopyrazine diol compounds as pi3k-y inhibitors
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN110483403A (en) * 2019-09-02 2019-11-22 南通大学 A kind of synthetic method of the bromo- 4- methoxyl group -1H- indazole of 5-

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007386A1 (en) 1989-11-21 1991-05-30 Schering Corporation Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
GB9004260D0 (en) 1990-02-26 1990-04-18 Pfizer Ltd Therapeutic agents
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

Also Published As

Publication number Publication date
BR0208455A (en) 2004-03-02
PA8542401A1 (en) 2002-10-28
WO2002079143A1 (en) 2002-10-10
CN1492852A (en) 2004-04-28
SK11822003A3 (en) 2004-09-08
TWI254038B (en) 2006-05-01
CA2437113A1 (en) 2002-10-10
HUP0303624A3 (en) 2005-06-28
NZ527012A (en) 2005-03-24
NO20034299D0 (en) 2003-09-26
EE200300469A (en) 2004-02-16
CZ20032534A3 (en) 2004-07-14
IL157009A0 (en) 2004-02-08
HK1060724A1 (en) 2004-08-20
MA26996A1 (en) 2004-12-20
IS6877A (en) 2003-07-17
AP1689A (en) 2006-12-07
EP1373192A1 (en) 2004-01-02
AR035795A1 (en) 2004-07-14
DOP2002000364A (en) 2002-10-15
AP2002002467A0 (en) 2002-06-30
BG108130A (en) 2004-07-30
KR100564466B1 (en) 2006-03-29
NO20034299L (en) 2003-11-27
EA200300777A1 (en) 2003-12-25
EA006154B1 (en) 2005-10-27
CN1243723C (en) 2006-03-01
JP4018545B2 (en) 2007-12-05
MXPA03006597A (en) 2004-10-15
OA12553A (en) 2006-06-07
HRP20030751A2 (en) 2005-08-31
UY27227A1 (en) 2002-10-31
HUP0303624A2 (en) 2004-03-01
JP2004531505A (en) 2004-10-14
GEP20063783B (en) 2006-04-10
RS75303A (en) 2006-12-15
MY134081A (en) 2007-11-30
TNSN02032A1 (en) 2005-12-23
KR20030092032A (en) 2003-12-03
PL365101A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
PE20021014A1 (en) GLUTARAMIDE DERIVATIVES SUBSTITUTED WITH N-FENPROPYL CYCLOPENTILO AS NEP INHIBITORS FOR FSAD
PE20081545A1 (en) SULFONAMIDE DERIVATIVES AS SYNTHASE FATTY ACID INHIBITORS
PE20020064A1 (en) NITRILE BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF CISTEIN PROTEASES
PE20050948A1 (en) CARBAMOIL-AMINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV
PE20070833A1 (en) PYRIMIDINYL BENZOTHIOPHENE COMPOUNDS
PE20040164A1 (en) MIMETICS OF GLUCOCORTICOIDS, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
PE20040775A1 (en) INDEOL DERIVATIVES AS ß2-ADRENORECEPTOR AGONISTS
PE20020476A1 (en) GLUCOPYRANOSILOXYBENZYLBENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
PE20060777A1 (en) INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
AR072331A2 (en) MANDELIC ACID DERIVATIVES, PHARMACEUTICAL FORMULATION, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS
PE20060352A1 (en) ARYL- OR HETEROARYLAMIDE ORTHOSUSTITUTED COMPOUNDS
PE20090813A1 (en) 11B-HYDROXIESTEROID-DEHYDROGENASE INHIBITORS
UY31986A (en) N-SUBSTITUTED DERIVATIVES OF 2-METHYL-PROPIONAMIDE; {1- [5-SUSTIUDED-4-SUBSTITUTED-TIAZOL-2-IL-CARBAMOIL] -1-METHYL-ETIL} AMIDAS OF SUBSTITUTED CARBOXYLIC ACIDS, PHARMACEUTICALLY ACCEPTED BY SAME, COMPOSITIONS AND APPLICATIONS.
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
PE20040844A1 (en) PHENYLACETIC ACIDS AND DERIVATIVES AS COX-2 INHIBITORS
PE20010984A1 (en) NITRILE DERIVATIVES AS CATEPSIN K INHIBITORS
DE60130771D1 (en) SUBSTITUTED HETEROCYCLIC AMIDS
AR047085A1 (en) DERIVATIVES OF (3-OXO-3,4-DIHIDRO-QUINOXALINA-2-IL-AMINO) BENZAMIDE AND RELATED COMPOUNDS AS INHIBITORS OF GLUCOGENO FOSFORILASA FOR THE TREATMENT OF DIABETES AND OBESITY
EA200600621A1 (en) DERIVATIVES OF TETRAHYDRONAPTALINE, METHOD OF THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY MEANS
MA29464B1 (en) PROCESS FOR THE PREPARATION OF OPTIONALLY 2-SUBSTITUTED 1,6-DIHYDRO-6-OXO-4-PYRIMIDINECARBOXYLIC ACIDS
PE20090548A1 (en) AZA-BICYCLOHEXANE COMPOUNDS AS THROMBIN INHIBITORS
EA200600605A1 (en) REJUVENATED PENTANOLS, METHOD OF THEIR PRODUCTION AND THEIR APPLICATION AS ANTI-INFLAMMATORY MEANS
PE20050160A1 (en) 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE
PE20050293A1 (en) DERIVATIVES OF AMINO ACIDS SUBSTITUTED WITH CYCLOALKYL, PROCEDURE FOR THEIR PREPARATION AND USE AS MEDICINES
PE20050312A1 (en) PEPTIDYL COMPOUNDS AS CATEPSIN S INHIBITORS

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed